[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572060":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":10},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"female migraine patients who recevie Rimegepant as prophylactic treatment",null,[12],"Drug: Rimegepant",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Rimegepant","Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"HongRu Zhao, M.D","CONTACT","18051212086","tiantan11@163.com",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100572060","the-real-world-study-of-rimegepant-treatment-in-female-migraine-patients-of-china-100572060",false,"NCT06728345","The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China","The Real-world Study of Rimegepant for the Preventive Treatment in Female Migraine Patients","Inclusion Criteria:\n\n1. Female participants aged ≥ 18 years-old\n2. Primary diagnosis of migraine according to ICHD-3 3.4 or more migraine days during Observation Period and Screening Visit\n\n4.Migraine attacks present for more than 1 year 5.Rimegepant is prescribed for the preventive treatment of migraine by physician 6.Written informed consent must be obtained before participant is enrolled 7.Not concurrently participating in other interventional clinical studies.\n\nExclusion Criteria:\n\n1. Patients diagnosed with secondary headaches.\n2. Women who are pregnant or breastfeeding.\n3. Subjects with severe impairments in language, vision, memory, or cognitive function that affect communication and understanding, or those who are unable to complete questionnaires or follow-ups.\n4. Subjects lacking the equipment to complete questionnaires on a digital platform.\n5. Subjects who are allergic to rimegepant or any of its excipients.\n6. Patients with severe liver damage or end-stage renal disease.\n7. Patients with a medical history indicating the presence of uncontrolled or unstable cardiovascular disease (such as ischemic heart disease, coronary artery spasm, or cerebral ischemia), or those who have had a myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within 6 months prior to the screening visit.\n8. Any condition deemed by the investigator that might affect the patient's participation in the study.","FEMALE","18 Years","65 Years",{"count":38,"type":39},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings :\n\n1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12\n2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12",[43,44],"Migraine","Migraine Prophylaxis","NOT_YET_RECRUITING","2024-12-06",{"date":48,"type":49},"2024-12-11","ACTUAL",{"date":51,"type":39},"2024-12-01",{"date":53,"type":39},"2027-12-31",{"name":5,"class":6}]